Tumor Mutational Burden (TMB) is a putative biomarker of response to checkpoint inhibitor therapy. Q2 Solutions | EA Genomics
offers a TMB assay that utilizes a whole exome sequencing (WES) of tumor specimens for reliable quantification of TMB across
various tumor indications.
Learn more about our TMB assay specifications and our comprehensive portfolio of genomic assays for immuno-oncology applications.